320 related articles for article (PubMed ID: 32391189)
1. Evaluation of PD-L1 expression on circulating tumor cells (CTCs) in patients with advanced urothelial carcinoma (UC).
Bergmann S; Coym A; Ott L; Soave A; Rink M; Janning M; Stoupiec M; Coith C; Peine S; von Amsberg G; Pantel K; Riethdorf S
Oncoimmunology; 2020; 9(1):1738798. PubMed ID: 32391189
[TBL] [Abstract][Full Text] [Related]
2. Liquid Biopsy Assessment of Circulating Tumor Cell PD-L1 and IRF-1 Expression in Patients with Advanced Solid Tumors Receiving Immune Checkpoint Inhibitor.
Kennedy LC; Lu J; Kuehn S; Ramirez AB; Lo E; Sun Y; U'Ren L; Chow LQM; Chen Z; Grivas P; Kaldjian EP; Gadi VK
Target Oncol; 2022 May; 17(3):329-341. PubMed ID: 35696014
[TBL] [Abstract][Full Text] [Related]
3. Programmed Cell Death Ligand 1-Expressing Circulating Tumor Cells: A New Prognostic Biomarker in Non-Small Cell Lung Cancer.
Sinoquet L; Jacot W; Gauthier L; Pouderoux S; Viala M; Cayrefourcq L; Quantin X; Alix-Panabières C
Clin Chem; 2021 Nov; 67(11):1503-1512. PubMed ID: 34355741
[TBL] [Abstract][Full Text] [Related]
4. PD-L1 expression in circulating tumor cells of advanced non-small cell lung cancer patients treated with nivolumab.
Guibert N; Delaunay M; Lusque A; Boubekeur N; Rouquette I; Clermont E; Mourlanette J; Gouin S; Dormoy I; Favre G; Mazieres J; Pradines A
Lung Cancer; 2018 Jun; 120():108-112. PubMed ID: 29748004
[TBL] [Abstract][Full Text] [Related]
5. PD-L1 Expression in Circulating Tumor Cells as a Promising Prognostic Biomarker in Advanced Non-small-cell Lung Cancer Treated with Immune Checkpoint Inhibitors.
Dall'Olio FG; Gelsomino F; Conci N; Marcolin L; De Giglio A; Grilli G; Sperandi F; Fontana F; Terracciano M; Fragomeno B; Tober N; Manferrari G; Brocchi S; Golfieri R; Fiorentino M; Ardizzoni A
Clin Lung Cancer; 2021 Sep; 22(5):423-431. PubMed ID: 33849808
[TBL] [Abstract][Full Text] [Related]
6. Circulating tumor cells PD-L1 expression detection and correlation of therapeutic efficacy of immune checkpoint inhibition in advanced non-small-cell lung cancer.
Zhou Q; Liu X; Li J; Tong B; Xu Y; Chen M; Liu X; Gao X; Shi Y; Zhao J; Zhong W; Wang M
Thorac Cancer; 2023 Feb; 14(5):470-478. PubMed ID: 36630992
[TBL] [Abstract][Full Text] [Related]
7. PD-L1 expression on circulating tumor cells and platelets in patients with metastatic breast cancer.
Darga EP; Dolce EM; Fang F; Kidwell KM; Gersch CL; Kregel S; Thomas DG; Gill A; Brown ME; Gross S; Connelly M; Holinstat M; Cobain EF; Rae JM; Hayes DF; Paoletti C
PLoS One; 2021; 16(11):e0260124. PubMed ID: 34780566
[TBL] [Abstract][Full Text] [Related]
8. Assessment of PD-L1 Expression on Circulating Tumor Cells for Predicting Clinical Outcomes in Patients with Cancer Receiving PD-1/PD-L1 Blockade Therapies.
Tan Z; Yue C; Ji S; Zhao C; Jia R; Zhang Y; Liu R; Li D; Yu Q; Li P; Hu Z; Yang Y; Xu J
Oncologist; 2021 Dec; 26(12):e2227-e2238. PubMed ID: 34516729
[TBL] [Abstract][Full Text] [Related]
9. Prognostic significance of PD-L1 expression on cell-surface vimentin-positive circulating tumor cells in gastric cancer patients.
Liu M; Wang R; Sun X; Liu Y; Wang Z; Yan J; Kong X; Liang S; Liu Q; Zhao T; Ji X; Wang G; Wang F; Wang G; Chen L; Zhang Q; Lv W; Li H; Sun M
Mol Oncol; 2020 Apr; 14(4):865-881. PubMed ID: 31981446
[TBL] [Abstract][Full Text] [Related]
10. PD-L1
Zhang L; Zhang X; Liu Y; Zhang T; Wang Z; Gu M; Li Y; Wang DD; Li W; Lin PP
Cancer Lett; 2020 Jan; 469():355-366. PubMed ID: 31678168
[TBL] [Abstract][Full Text] [Related]
11. Detection of PD-L1 in circulating tumor cells and white blood cells from patients with advanced non-small-cell lung cancer.
Ilié M; Szafer-Glusman E; Hofman V; Chamorey E; Lalvée S; Selva E; Leroy S; Marquette CH; Kowanetz M; Hedge P; Punnoose E; Hofman P
Ann Oncol; 2018 Jan; 29(1):193-199. PubMed ID: 29361135
[TBL] [Abstract][Full Text] [Related]
12. Programmed Cell Death Ligand 1 Expression in Circulating Tumor Cells as a Predictor of Treatment Response in Patients with Urothelial Carcinoma.
Chiang PJ; Xu T; Cha TL; Tsai YT; Liu SY; Wu ST; Meng E; Tsao CW; Kao CC; Chen CL; Sun GH; Yu DS; Chang SY; Yang MH
Biology (Basel); 2021 Jul; 10(7):. PubMed ID: 34356529
[TBL] [Abstract][Full Text] [Related]
13. Dynamic monitoring of PD-L1 and Ki67 in circulating tumor cells of metastatic non-small cell lung cancer patients treated with pembrolizumab.
Spiliotaki M; Neophytou CM; Vogazianos P; Stylianou I; Gregoriou G; Constantinou AI; Deltas C; Charalambous H
Mol Oncol; 2023 May; 17(5):792-809. PubMed ID: 36177552
[TBL] [Abstract][Full Text] [Related]
14. Potential role of nuclear PD-L1 expression in cell-surface vimentin positive circulating tumor cells as a prognostic marker in cancer patients.
Satelli A; Batth IS; Brownlee Z; Rojas C; Meng QH; Kopetz S; Li S
Sci Rep; 2016 Jul; 6():28910. PubMed ID: 27363678
[TBL] [Abstract][Full Text] [Related]
15. Frequent expression of PD-L1 on circulating breast cancer cells.
Mazel M; Jacot W; Pantel K; Bartkowiak K; Topart D; Cayrefourcq L; Rossille D; Maudelonde T; Fest T; Alix-Panabières C
Mol Oncol; 2015 Nov; 9(9):1773-82. PubMed ID: 26093818
[TBL] [Abstract][Full Text] [Related]
16. Prognostic significance of PD-L1 expression on circulating tumor cells in patients with head and neck squamous cell carcinoma.
Strati A; Koutsodontis G; Papaxoinis G; Angelidis I; Zavridou M; Economopoulou P; Kotsantis I; Avgeris M; Mazel M; Perisanidis C; Sasaki C; Alix-Panabières C; Lianidou E; Psyrri A
Ann Oncol; 2017 Aug; 28(8):1923-1933. PubMed ID: 28838214
[TBL] [Abstract][Full Text] [Related]
17. Characterization of Urothelial Cancer Circulating Tumor Cells with a Novel Selection-Free Method.
Chalfin HJ; Kates M; van der Toom EE; Glavaris S; Verdone JE; Hahn NM; Pienta KJ; Bivalacqua TJ; Gorin MA
Urology; 2018 May; 115():82-86. PubMed ID: 29432873
[TBL] [Abstract][Full Text] [Related]
18. Discordance of high PD-L1 expression in primary and metastatic urothelial carcinoma lesions.
Burgess EF; Livasy C; Hartman A; Robinson MM; Symanowski J; Naso C; Doherty S; Guerrieri R; Riggs S; Grigg CM; Clark PE; Raghavan D
Urol Oncol; 2019 May; 37(5):299.e19-299.e25. PubMed ID: 30660491
[TBL] [Abstract][Full Text] [Related]
19. Clinicopathologic and Genomic Characterization of PD-L1 Positive Urothelial Carcinomas.
Huang RSP; Haberberger J; Harries L; Severson E; Duncan DL; Ferguson NL; Hemmerich A; Edgerly C; Murugesan K; Xiao J; McEwan D; Holmes O; Hiemenz M; Venstrom J; Elvin JA; Creeden J; Lin DI; Ross JS; Ramkissoon SH
Oncologist; 2021 May; 26(5):375-382. PubMed ID: 33687775
[TBL] [Abstract][Full Text] [Related]
20. High Specificity in Circulating Tumor Cell Identification Is Required for Accurate Evaluation of Programmed Death-Ligand 1.
Schehr JL; Schultz ZD; Warrick JW; Guckenberger DJ; Pezzi HM; Sperger JM; Heninger E; Saeed A; Leal T; Mattox K; Traynor AM; Campbell TC; Berry SM; Beebe DJ; Lang JM
PLoS One; 2016; 11(7):e0159397. PubMed ID: 27459545
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
